(Q36164013)

12 August 2017

1 reference

title

Capecitabine: effective oral fluoropyrimidine chemotherapy (English)

1 reference

12 August 2017

1 reference

1 reference

Joseph McKendrick

1

1 reference

12 August 2017

John Coutsouvelis

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

1231-1239

1 reference

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Clinical pharmacokinetics of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Population pharmacokinetic analysis of the major metabolites of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Cutaneous Hand and Foot Toxicity Associated With Cancer Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.7.1231

10.1517/14656566.6.7.1231

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference